886365-25-9

Basic information

• Product Name: 5-BROMO-2-METHOXY-ISONICOTINIC ACID METHYL ESTER
• Synonyms: 5-BROMO-2-METHOXY-ISONICOTINIC ACID METHYL ESTER;Methyl 5-bromo-2-methoxypyridine-4-carboxylate;Methyl 5-bromo-2-methoxyisonicotinate
• CAS NO: 886365-25-9
• Molecular Formula: C8H8BrNO3
• Molecular Weight: 246.05802
• EINECS: 811-258-6
• Mol File: 886365-25-9.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 5-BROMO-2-METHOXY-ISONICOTINIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-2-METHOXY-ISONICOTINIC ACID METHYL ESTER(886365-25-9)
• EPA Substance Registry System: 5-BROMO-2-METHOXY-ISONICOTINIC ACID METHYL ESTER(886365-25-9)

Safety Data

• Hazardous Substances Data: 886365-25-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
5-BROMO-2-METHOXY-ISONICOTINIC ACID METHYL ESTER is used as a research compound for its potential as an anti-cancer agent. It has been studied for its ability to inhibit the growth of cancer cells, making it a promising candidate for the development of new drugs and therapies for cancer treatment.
Used in Organic Synthesis:
5-BROMO-2-METHOXY-ISONICOTINIC ACID METHYL ESTER is used as a key intermediate in the synthesis of various pharmaceuticals and biologically active compounds. Its unique structure allows for the creation of new molecules with potential therapeutic applications.
Used in Cancer Treatment Development:
5-BROMO-2-METHOXY-ISONICOTINIC ACID METHYL ESTER is used as a starting material in the development of new drugs and therapies for cancer treatment. Its potential as an anti-cancer agent has been recognized, and ongoing research aims to harness its properties to improve patient outcomes and combat various types of cancer.

Upstream product

• 67-56-1 methanol 
• 886365-22-6 5-bromo-2-methoxypyridine-4-carboxylic acid 
• 936011-17-5 5-bromo-2-methoxy-pyridine-4-carbaldehyde 
• 13472-85-0 2-methoxy-5-bromopyridine 
• 74-88-4 methyl iodide 

Downstream Products

• 913836-16-5 C₆H₄BrNO₃ 
• 913836-17-6 methyl 5-bromo-2-oxo-1,2-dihydropyridine-4-carboxylate 
• 1060816-46-7 7-methoxy-1,2,3,4-tetrahydro-2,6-naphthyridine 
• 886365-22-6 5-bromo-2-methoxypyridine-4-carboxylic acid 
• 1590407-03-6 C₁₉H₁₀F₄N₂O₂ 
• 1590403-91-0 C₂₆H₁₈F₄N₂O₃ 
• 1590403-90-9 C₁₉H₁₁F₄NO₄ 
• 1590411-04-3 C₁₉H₁₂F₄N₂O₃ 
• 1590411-03-2 C₂₀H₁₃F₄NO₄ 

Relevant articles and documents

BICYCLIC HETEROCYCLE COMPOUNDS METHODS OF USE THEREOF FOR THE TREATMENT OF HERPES VIRUSES

The present invention relates to novel Bicyclic Heterocycle Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, X, Y, Z, R1 R5, R6, and R7 are as defined herein. The present invention also relates to compositions comprising

THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS

Disclosed herein are certain thiadiazolyl derivatives Formula (I): that inhibit DNA Polymerase Theta (Polθ) activity, in particular inhibit Polθ activity by inhibiting ATP dependent helicase domain activity of Polθ. Also, disclosed are pharmaceutical compositions comprising such compounds and methods of treating and/or preventing diseases treatable by inhibition of Polθ such as cancer, including homologous recombination (HR) deficient cancers.

BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF

The invention provides novel compounds having the general formula (I) wherein R1, X, Zlto Z5, L, n, the A ring, and the B ring, are as described herein, pharmaceutical compositions including the compounds and methods of using the compounds.Compounds (I) act as inhibitors of RIP1 kinase.

NOVEL TETRAHYDROISOQUINOLINES AND TERAHYDRONAPHTHYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION

The present invention provides novel compounds having the general formula (I): wherein R1, R 2, R 3, U, V, W, X and Y are as described herein, compositions including the compounds and methods of using the compounds.

ANTI-FIBROTIC PYRIDINONES

This application relates to polycyclic compounds with a pyridinone or pyridinone derivative core including, substituted pyridinones, 5,6- and 6,6- bicyclic heterocycles and substituted pyridine-thiones. This application also discloses methods of preparing these polycyclic compounds, pharmaceutical compositions and medicaments comprising said compounds and methods to treat, prevent or diagnose diseases, disorders or conditions associated with fibrosis.

ANTI-FIBROTIC PYRIDINONES

Disclosed are pyridinone compounds, method for preparing these compounds, and methods for treating fibrotic disorders.